PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC12207141::ACT019621

LCKLSL

Evidence text

Paper-level observation

Figure 5D: The decreased Annexin A2-immunoprecipitated HSP90 and the decreased HSP90-immunoprecipitated Annexin A2 under the treatments of ... 10 µM hexapeptide LCKLSL (HEXA).
figureConfidence: medium

Assay observation

Activity
Immunomodulatory
Subtype
Antibacterial
Measure
percent_inhibition
Comparator
=
Raw observation
decreased
Normalized measurement
=0
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Huh-7
Assay method
Not reported by source
Sequence
LCKLSL
Standardization
ready simple

Source publication

Targeting Annexin A2 to reactivate tumor-associated antigens presentation and relieve immune tolerance in liver cancer.

Journal for Immunotherapy of Cancer · 2025

DOI 10.1136/jitc-2025-011716 PMC12207141
Parent mention

Related peptide identities

PEPDIA-PLP-001707

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.